

NICE Systems

(Bloomberg Ticker : NICE US)

Nice performance, expensively priced stock Downgraded to Underperform

The company's results in recent quarters have been iffy, and yet the stock trades at 20.4 times anticipated FY2010 results. The firm's hefty cash holding is yielding virtually nothing. The stock is expensive. Management hasn't offered guidance for either Q4 '09 or FY2010, and we believe the improved performance the consensus has penciled in will prove to be overly-optimistic. We're accordingly downgrading the stock to Underperform, while leaving our per-share price target intact at \$30.

Outlook for 2010. Excluding the results of the three acquisitions made in 2009, we look for organic growth at a single digit pace for the year under way. Nice trades at a P/E multiple of 20.4, based on our forecast for 2010 net income and 19.4 times consensus earnings projections, which we believe overly optimistic.

As the global macro backdrop improves, IT budgets will continue rising, supported by more stringent regulatory standards, which should benefit Nice subsidiary Actimize, which operates in the financial services sector. However, even if the global crisis has been brought to heel, we believe Nice's enterprise-product customers will continue keeping expenses under tight rein, seeing that improved corporate results have been the result of cost cutbacks and strict cash-flow management, not top-line growth. A recent large security-segment transaction, totaling \$55m, instills us with an element of confidence over Nice's 2010 results. But the company's current share price, in our judgment, is discounting a greater number of large transactions than we believe are likely to come to fruition.

Outlook for Q4. Management has refrained from providing guidance for the quarter under way, but has said that Q4 and FY2010 will see year-on-year growth. The new chief executive is now fully in control, but he could experience difficulties maintaining the tight budgetary expenditures that prevailed throughout 2009.

Cash horde. Nice has \$518m on its books, representing \$8.26 a share, even after the acquisition of Hexagon and Fortent for \$84.5m, but not including the pending \$22m acquisition of Orsus. Nice made only three small acquisitions during the global crisis, despite its substantial cash holding. With stock markets having come back substantially, the odds of a major acquisition have declined.


Dollar weakness. The dollar's decline against the shekel won't have a dramatic impact on the company's results in Q4 thanks to hedging the company has in place. But continued dollar weakness may create difficulties for the company, and could lead to additional cost cutting.

Updates

- Rating**
- Price target**
- Forecast**

Key figures

Rating	Underperform
Price target (\$)	30.0
Current price (\$)	33.0
Market cap (B' \$)	2.1
12-mo. Change (ADR)	41%
12-mo. Change TA-25	68%
12-mo. high (\$)	34.3
12-mo. low (\$)	18.0
Daily volume (m' NIS)	23
Free float	99%
Non GAAP P/E 2009E	22.2
Non GAAP P/E 2010E	20.4
EV/EBITDA 09E	13.6
EV/EBITDA 10E	11.5
Previous rating	Market Perform
Previous PT (\$)	30



NICE M\$ (NON GAAP)	4Q08	3Q09	4Q09E	2008	2009E
Total Revenue	163.3	146.1	155.8	628.4	581.5
YoY	12.1%	-10.4%	-4.6%	20.2%	-7.5%
Gross Profit	106.8	91.79	99.9	409.4	368.1
Gross margin	65.4%	62.8%	64.2%	65.1%	63.3%
YoY	13.2%	-13.1%	-6.4%	23.4%	-10.1%
Operting Income	30.1	24.9	29.4	109.4	102.2
Operting margin	18.4%	17.0%	18.9%	17.4%	17.6%
YoY	17.6%	-17.8%	-2.3%	25.4%	-6.5%
Net Income	30.6	24.0	25.0	103.2	92.4
Net margin	18.7%	16.4%	16.0%	16.4%	15.9%
YoY	27.0%	-10.2%	-18.3%	26.8%	-10.5%
Diluted EPS (without options)	0.50	0.38	0.40	1.68	1.48
YoY	27.9%	-12.0%	-20.4%	16.3%	-11.5%

Clal Finance Brokerage Ltd.

NICE M\$ (NON GAAP)	2007	2008	1Q09	2Q09	3Q09	4Q09E	2009E	2010E	2011E	2012E
Product	319.5	353.6	68.6	65.7	69.7	82.6	286.6	321.7	349.8	372.6
% of revenues	61.1%	56.3%	49.3%	46.7%	47.7%	53.0%	49.3%	49.9%	49.8%	49.8%
YoY	20.7%	10.7%	-19.5%	-26.1%	-20.8%	-9.8%	-19.0%	12.2%	8.7%	6.5%
Services	203.2	274.7	70.6	74.8	76.3	73.2	294.9	323.6	352.5	376.2
YoY	32.5%	35.2%	14.8%	12.6%	1.8%	1.9%	7.3%	9.7%	8.9%	6.7%
Total Revenue	522.7	628.4	139.2	140.5	146.1	155.8	581.5	645.2	702.2	748.8
YoY	25.0%	20.2%	-5.1%	-9.6%	-10.4%	-4.6%	-7.5%	11.0%	8.8%	6.6%
Gross Profit	331.7	409.4	88.0	88.3	91.8	99.9	368.1	409.6	447.1	478.1
Gross margin	63.5%	65.1%	63.2%	62.9%	62.8%	64.2%	63.3%	63.5%	63.7%	63.9%
YoY	31.3%	23.4%	-7.7%	-13.1%	-13.1%	-6.4%	-10.1%	11.3%	9.2%	7.0%
R&D	55.5	72.6	17.1	16.7	17.8	18.7	70.3	76.7	82.7	87.5
% R&D	10.6%	11.5%	12.3%	11.9%	12.2%	12.0%	12.1%	11.9%	11.8%	11.7%
S&M	114.0	141.1	32.0	32.6	33.5	35.4	133.4	144.1	154.8	162.8
% S&M	21.8%	22.5%	23.0%	23.2%	22.9%	22.7%	22.9%	22.3%	22.0%	21.7%
G&A	75.0	86.4	15.6	14.4	15.6	16.5	62.2	66.4	70.9	74.1
% G&A	14.3%	13.7%	11.2%	10.3%	10.7%	10.6%	10.7%	10.3%	10.1%	9.9%
Operating expenses	244.5	300.0	64.7	63.7	66.9	70.6	265.8	287.2	308.4	324.3
% of revenue	46.8%	47.7%	46.4%	45.4%	45.8%	45.3%	45.7%	44.5%	43.9%	43.3%
Operating Income	87.2	109.4	23.3	24.6	24.9	29.4	102.2	122.3	138.7	153.8
Operating margin	16.7%	17.4%	16.8%	17.5%	17.0%	18.9%	17.6%	19.0%	19.8%	20.5%
YoY	37.9%	25.4%	0.0%	-4.1%	-17.8%	-2.3%	-6.5%	19.7%	13.4%	10.9%
Financial income	14.8	15.8	2.8	1.8	1.6	1.5	7.7	6.8	6.8	6.8
Income before taxes	102.0	125.2	26.1	26.4	26.5	30.8	109.9	129.2	145.5	160.6
taxes	20.6	21.9	4.8	4.4	2.5	5.9	17.5	26.5	30.6	33.7
Tax rate	20.2%	17.5%	18.3%	16.6%	9.5%	19.0%	16.0%	20.5%	21.0%	21.0%
Net Income	81.4	103.2	21.3	22.1	24.0	25.0	92.4	102.7	115.0	126.9
Net margin	15.6%	16.4%	15.3%	15.7%	16.4%	16.0%	15.9%	15.9%	16.4%	16.9%
YoY	33.4%	26.8%	-3.1%	-7.9%	-10.2%	-18.3%	-10.5%	11.2%	11.9%	10.4%
Diluted EPS	1.44	1.68	0.35	0.36	0.38	0.40	1.48	1.62	1.78	1.92
YoY	23.6%	16.3%	-3.0%	-7.9%	-12.0%	-20.4%	-11.5%	9.1%	9.8%	8.2%
Number of shares (diluted)	56.3	61.6	61.6	61.8	62.8	63.0	62.3	63.5	64.8	66.1
One Time -Cash items					0.0	0.0	2.2	0.0	0.0	0.0
Working Capital					(5.7)	5.0	(16.3)	7.6	5.7	4.7
Depreciation					3.4	3.3	12.7	12.7	13.3	14.0
CAPEX					2.5	4.7	12.7	17.4	20.4	21.7
Acquisition					80.5	4.0	88.9	22.0	-	-
FCF	84.6	87.5	28.3	20.0	(54.7)	17.2	10.8	61.5	95.4	107.7

NICE DCF		g				
WACC	35.1	2.0%	2.5%	3.0%	3.5%	4.0%
	8.3%	31.2	33.0	35.1	37.7	40.9
	8.8%	29.4	30.9	32.6	34.7	37.3
	9.3%	27.8	29.1	30.6	32.3	34.4
	9.8%	26.4	27.5	28.8	30.2	32.0
	10.3%	25.2	26.2	27.2	28.5	29.9

Clal Finance Brokerage Ltd.

Clal Finance Brokerage Ltd.			
Israeli Desk			
Ronen Wassserberg CEO +972-3-5653546 ronen@clal-fin.co.il	Neor El-Hai Head of Trading +972-3-5653552 neor@clal-fin.co.il	Moshe Ben Assayag +972-3-5653550 mosheba@clal-fin.co.il	Hagit Dalal +972-3-5653543 hagitd@clal-fin.co.il
Arieh Lantsberg +972-3-5653542 ariehl@clal-fin.co.il	Roni Sassover +972-3-7611986 ronis@clal-fin.co.il		
International Desk			
Saar Golan International Equity Sales & Trading +972-3-5651987 saar@clal-fin.co.il	Avi Weinreb International Equity Sales & Trading +972-3-5653556 aviwe@clal-fin.co.il		
International Bonds			
Yisca Erez +972-3-6251037 yisca@clal-fin.co.il	Yael Atzmon +972-3-5652510 yaelat@clal-fin.co.il		
Govt. Bonds	Options	Client Relations	Back Office
Dror Wasserman +972-3-7611904 drorw@clal-fin.co.il	Tsahi Sokol +972-3-7616450 tzahiso@clal-fin.co.il	Marisa Bender +972-3-6251014 marisab@clal-fin.co.il	Betty Mizrahi +972-3-5653537 betty@clal-fin.co.il
Research			
Yuval Ben Ze'ev Head of Research Financial, Holding and Real Estate +972-3-5653559 yuvalb@clal-fin.co.il	Tsahi Avraham Tech / Telecom +972-3-5652510 tsahiav@clal-fin.co.il	Aviran Nevivo Chemicals +972-3-5652510 aviranr@clal-fin.co.il	Gal Reiter Pharma, Energy +972-3-7616407 galbz@clal-fin.co.il

Warning notes and full disclosure concerning this analysis**a. Details on the author of the analysis**

Tsahi Avraham

ID No. 038543500

Investment Marketing License # 7553

37, Menachem Begin Road, Tel Aviv

Education: MA Economics and Business Management, Hebrew University; BA Accounting and Economics, Hebrew University.

Experience – Research and analytical roles from 2001 to date (the last 7 years) in the following companies: Clal Finance Investment Management, Infiniti Group, ERCG (Economic Research & Consulting Group), Bank of Israel – Research Dept.

The company for which the author prepared this analysis:

Clal Finance Investments Management Ltd.,

37 Menachem Begin Road, Tel Aviv

Tel: 03 565-3557

b. Full disclosure by the author of this analysis

As far as he is aware, the author of this analysis does not have any conflict of interest at the time of its publication.

c. Notes on the analysis**1. Scale of recommendations**

- **Buy** – the stock is expected to out perform TA100 by 20% or more in 12 months.
- **Outperform** - the stock is expected to out perform TA100 by 10% to 20% in 12 months.
- **Marketperform** – the stock is expected to out perform/ under perform TA100 by 10 % in 12 months.
- **Underperform** – the stock is expected to under perform TA100 by 10% to 20% in 12 months.
- **Sell** – the stock is expected to under perform TA100 by 20% or more in 12 months.

2. The method used in setting our price target for Nice Systems combined a discounted cash flow model with market-to-book multiples and price-earnings ratios of other companies in the sector, which were compared with those of Nice.

3. The main risks with the potential of materially affecting the price target of Nice's shares include the following:

- Difficulties in integrating the operations of Actimize, and/or creating synergies, or similar difficulties in assimilating any future acquisitions, thereby impairing the company's ability to attain its self-declared financial objectives.
- Sector-wide technological developments that could negatively affect the company should it fail to adapt itself with sufficient alacrity to the new environment.
- The company's dependence on external suppliers, including software suppliers. Such suppliers could fail to meet the company's needs in terms of quality and/or quantity.
- Loss of its principal distributor, Avaya, which would have a materially damaging affect on the company's sales.

d. Independent Judgment

I, Tsahi Avraham, License Number 7553, declare that the opinions stated in this analysis faithfully represent my personal opinions about the shares reviewed and the corporation which issued these shares.

Tsahi Avraham

e. **Full disclosure on behalf of Clal Finance Investments Management Ltd. (henceforth "The licensed Corporation")**. Hereafter is full disclosure on conflict of interest by the licensed Corporation, as far as known or that there is a risk for its existence at the time of the publication of this analysis:

1. On the publication date of this analysis or during the preceding 30 days, the licensed Corporation or, to the best knowledge of the licensed Corporation, corporations connected to it, held by it, in their Nostro accounts or in accounts managed by them, significant holdings of a certain type of shares of Nice.
2. Date of publication. This research report was issued on Nov. 04, 2009, following the company's Q2 earnings release.

f. Comments and general warnings by Clal Finance Investments Management Ltd.

The analysis in this report is for information purposes only. It should not be seen as a proposal or advice to purchase and/or sale and/or holding of the shares and/or financial assets described in the report.

The analysis is published based on information which was available to the general public as well as other information, including information which was published by the company which is the subject of this report, and which Clal Finance believes to be credible; no independent tests were performed to determine the credibility of the information. The information appearing in this report does not try to represent all the information required for any investor and therefore does not attempt to be a full analysis of all the facts and details in the report and the opinions stated are likely to change without any additional announcement.

This report does not in any way negate the need for investment counseling which takes account of the data and special needs of each person.

Clal Finance Batucha, companies under its control and shareholders and their employees are not responsible in any way for damage and/or loss caused by use of this report, if caused and therefore, cannot guarantee or be responsible for the reliability of the data published in this report.

Clal Finance belongs to the I.D.B. group of companies.

Clal Finance Group which includes Clal Finance Batucha, deals among other things, in management of investment portfolios, share trading, investments marketing and activity in the stock exchange and in investment banking.

Furthermore, companies under its control and owners of its share, or other bodies connected with it one way or another, holding or may be holding, from time to time, directly and/or indirectly in shares of the companies in this report, prior, during or after its publication.

Furthermore, since Clal Finance Batucha, companies under its control, its shareholders or other bodies associated with it, bodies dealing in underwriting, may serve as underwriters of the report's company shares and may be associated with it in business dealings.

In addition, Clal Finance serves as a market maker of shares for various companies, through authorization of the Tel Aviv Stock Market Ltd., and may serve as the market maker for the company which is the subject of this report.

Yuval Ben Ze'ev, the research manager for Clal Finance Brokerage, subsidiary of Clal Finance Batucha, is an interested party in Clal Finance Brokerage.

This report is intended for the addressee whose name appears above. Transfer of portions of its content to other parties, or publication in any way, without prior approval in writing from Clal Finance Batucha, and without inclusion of this warning note in the text body, in a prominent place, is forbidden if not otherwise stated.